Kirkland & Ellis is advising Patient Square Capital, a dedicated health care investment firm, on its investment in Apollo Therapeutics, a portfolio-based biopharmaceutical company established by three leading UK universities, GlaxoSmithKline, Astra Zeneca and Johnson & Johnson Innovation, for rapidly advancing potentially transformative therapeutic programs based on breakthrough discoveries. Patient Square Capital will take a controlling position in the business, with participation from additional investors including Rock Springs Capital, Reimagined Ventures and UCL Technology Fund. Proceeds from the investment will support advancement of Apollo’s pipeline into development and expansion of the company’s operations including establishment of a presence in the Boston, MA area and pursuit of new collaborations globally.
Read the Patient Square Capital press release
The Kirkland team involved a multi-office collaboration led by London corporate partners Carlos Gil Rivas, David Holdsworth and Matthew Elliott and U.S. investment funds partner David King, corporate partner Michael Weisser and tax partner Lee Morlock. The team was supported by corporate associates Syed Murshed, Niklas Ahlklo and Hannah Frost and investment funds associates Courtney Chen and Erin Choo.